Compare LTRN & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LTRN | COCH |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 51.3M |
| IPO Year | 2020 | 2021 |
| Metric | LTRN | COCH |
|---|---|---|
| Price | $0.40 | $6.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $17.50 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 217.0K | 31.8K |
| Earning Date | 12-01-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.65 | 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.38 | $4.72 |
| 52 Week High | $4.34 | $47.70 |
| Indicator | LTRN | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 25.77 | 19.48 |
| Support Level | N/A | $4.72 |
| Resistance Level | $0.84 | $7.46 |
| Average True Range (ATR) | 0.09 | 0.47 |
| MACD | 0.01 | 1.04 |
| Stochastic Oscillator | 3.10 | 58.20 |
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.